Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis

ConclusionsIn AMPLE, despite similar clinical outcomes, data showed that pharmacodynamic/genetic changes after 2  years of abatacept or adalimumab were consistent with drug MoAs. Further assessment of the relationship between such changes and clinical outcomes, including prediction of response, is warranted.Trial RegistrationClinicalTrials.gov identifier, NCT00929864.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research